Cardinal Health entered a feasibility agreement with Wyeth to develop cell lines using Cardinal Health’s Gene Product Expression (GPEx®) cell line engineering technology.
Cardinal Health will use the technology to engineer cell lines that express two undisclosed biopharmaceutical molecules in experiments that will determine if the GPEx approach is a feasible augmentation to Wyeth’s current production methods.
In addition to enabling rapid cell line development and availability of candidate gene products, the GPEx technology is “well suited for both efficient pilot and large-scale production of antibodies and other therapeutic recombinant proteins,” notes Paul Weiss, Ph.D., president of Cardinal Health’s biopharmaceutical development services center.
